taurine has been researched along with Fragile X Syndrome in 11 studies
Fragile X Syndrome: A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226)
Excerpt | Relevance | Reference |
---|---|---|
"Several off-label studies have shown that acamprosate can provide some clinical benefits in youth with Fragile X Syndrome (FXS), an autism spectrum disorder caused by loss of function of the highly conserved FMR1 gene." | 7.88 | Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome. ( Bantel, AP; Hutson, RL; Tessier, CR; Thompson, RL, 2018) |
"Plasma APP derivative levels pre- and post-treatment with acamprosate were determined in two pilot studies involving youth with idiopathic and fragile X syndrome (FXS)-associated ASD." | 7.80 | Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. ( Bowers, K; Erickson, CA; Lahiri, DK; Maloney, B; McDougle, CJ; Ray, B; Schaefer, TL; Sokol, DK; Wink, LK, 2014) |
" We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism." | 7.76 | Brief report: acamprosate in fragile X syndrome. ( Erickson, CA; McDougle, CJ; Mullett, JE, 2010) |
"Acamprosate was generally safe and well tolerated and was associated with a significant improvement in social behavior and a reduction in inattention/hyperactivity." | 6.78 | Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. ( Early, MC; Erickson, CA; Lahiri, DK; Mathieu-Frasier, L; McDougle, CJ; Patrick, V; Ray, B; Stiegelmeyer, E; Wink, LK, 2013) |
"Several off-label studies have shown that acamprosate can provide some clinical benefits in youth with Fragile X Syndrome (FXS), an autism spectrum disorder caused by loss of function of the highly conserved FMR1 gene." | 3.88 | Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome. ( Bantel, AP; Hutson, RL; Tessier, CR; Thompson, RL, 2018) |
"Plasma APP derivative levels pre- and post-treatment with acamprosate were determined in two pilot studies involving youth with idiopathic and fragile X syndrome (FXS)-associated ASD." | 3.80 | Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. ( Bowers, K; Erickson, CA; Lahiri, DK; Maloney, B; McDougle, CJ; Ray, B; Schaefer, TL; Sokol, DK; Wink, LK, 2014) |
" We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism." | 3.76 | Brief report: acamprosate in fragile X syndrome. ( Erickson, CA; McDougle, CJ; Mullett, JE, 2010) |
"Acamprosate was generally safe and well tolerated and was associated with a significant improvement in social behavior and a reduction in inattention/hyperactivity." | 2.78 | Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. ( Early, MC; Erickson, CA; Lahiri, DK; Mathieu-Frasier, L; McDougle, CJ; Patrick, V; Ray, B; Stiegelmeyer, E; Wink, LK, 2013) |
"Fragile X syndrome is an X-linked dominant disorder and the most common cause of inherited mental retardation." | 1.51 | Role of Taurine in Testicular Function in the Fragile x Mouse. ( El Idrissi, A; Lin, S, 2019) |
"Fragile X Syndrome is the most common known genetic cause of autism." | 1.36 | Taurine regulation of short term synaptic plasticity in fragile X mice. ( El Idrissi, A; L'Amoreaux, W; Neuwirth, LS, 2010) |
"Taurine treatment resulted in a significant increase in the number and size of islets." | 1.36 | Neuro-endocrine basis for altered plasma glucose homeostasis in the Fragile X mouse. ( El Idrissi, A; L'Amoreaux, W; Sidime, F; Yan, X, 2010) |
"The Fragile X syndrome, a common form of mental retardation in humans, is caused by silencing the fragile X mental retardation (FMR1) gene leading to the absence of the encoded fragile X mental retardation protein 1 (FMRP)." | 1.31 | Alterations of amino acids and monoamine metabolism in male Fmr1 knockout mice: a putative animal model of the human fragile X mental retardation syndrome. ( Braun, K; Gruss, M, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 9 (81.82) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lin, S | 1 |
El Idrissi, A | 5 |
Hutson, RL | 1 |
Thompson, RL | 1 |
Bantel, AP | 1 |
Tessier, CR | 1 |
Erickson, CA | 3 |
Wink, LK | 2 |
Ray, B | 2 |
Early, MC | 1 |
Stiegelmeyer, E | 1 |
Mathieu-Frasier, L | 1 |
Patrick, V | 1 |
Lahiri, DK | 2 |
McDougle, CJ | 3 |
Maloney, B | 1 |
Bowers, K | 1 |
Schaefer, TL | 1 |
Sokol, DK | 1 |
Hagerman, RJ | 1 |
Polussa, J | 1 |
Neuwirth, LS | 2 |
Volpe, NP | 1 |
Ng, S | 1 |
Marsillo, A | 1 |
Corwin, C | 1 |
Madan, N | 1 |
Ferraro, AM | 1 |
Boukarrou, L | 1 |
Dokin, C | 1 |
Brown, WT | 1 |
Mullett, JE | 1 |
L'Amoreaux, W | 2 |
Yan, X | 1 |
Sidime, F | 1 |
Gruss, M | 1 |
Braun, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Pilot Study of Acamprosate in Youth With Fragile X Syndrome[NCT01300923] | Phase 2 | 14 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The ADHD Rating Scale is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder. The ADHD Rating Scale-IV is completed by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. The total score can range from 0 to 54, with a higher score indicating greater severity. (NCT01300923)
Timeframe: Week 10
Intervention | units on a scale (Mean) |
---|---|
Acamprosate Treatment Group | 16.7 |
BDNF is a protein that supports the survival of existing neurons and growth and differentiation of new neurons and synapses. (NCT01300923)
Timeframe: Screen and Week 10
Intervention | pg/mL (Mean) |
---|---|
Acamprosate Treatment Group | 1,007.6 |
The Children's Yale-Brown Obsessive Compulsive Scales-Modified (CY-BOCS) is a 5-item, semi-structured clinician rating scale modified designed to rate the current severity of repetitive behavior in children and adolescents with PDD. Once the current repetitive behaviors are identified, they are separately rated on 5 items: Time Spent, Interference, Distress, Resistance, and Control. Each of these items is scored on a 5-point scale form 0 (least symptomatic) to 4 (most symptomatic). The CY-BOCS yields a Total Score from 0 to 20 and is sensitive to change. (NCT01300923)
Timeframe: Week 10
Intervention | units on a scale (Mean) |
---|---|
Acamprosate Treatment Group | 9.8 |
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. (NCT01300923)
Timeframe: Week 10
Intervention | units on a scale (Mean) |
---|---|
Acamprosate Treatment Group | 7.0 |
The Peabody Picture Vocabulary Test is one of the most commonly used assessment tests that measure verbal ability in standard American English vocabulary. This test has been nationally standardized using examinees from various age groups, from children to adults. Thus, the raw scores are equated to mental age, using the norms obtained from standardization. The total standard scores range from 40 (worse receptive vocabulary) to 160 (better receptive vocabulary). The scores can also be converted to percentile rank. (NCT01300923)
Timeframe: Week 10
Intervention | units on a scale (Mean) |
---|---|
Acamprosate Treatment Group | 83.3 |
The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The score of each individual item is summed to create a total raw score. A total scores results are as follows: 0-62: Within normal limits 63-79: Mild range of impairment 80-108: Moderate range of impairment 109-149: Severe range of impairment (NCT01300923)
Timeframe: Week 10
Intervention | units on a scale (Mean) |
---|---|
Acamprosate Treatment Group | 76.4 |
The Aberrant Behavior Checklist (ABC) is a 58-item rating scale used to assess maladaptive behaviors across five original subscales: Irritability (15 items from 0-45), Social Withdrawal (16 items from 0-48), Stereotypy (7 items from 0-21), Hyperactivity (16 items from 0-48), Inappropriate Speech (4 items from 0-12). Additionally, Social Avoidance, a newly developed four-item subscale (from 0-12) of the ABC that captures core social avoidance aspects of Fragile X Syndrome is reported. All items on the ABC are rated from 0 (not at all a problem) to 3 (the problem is severe in degree). Higher scores indicate greater maladaptive behaviors. Differences between Baseline and Week 10 are used as an indicator of change. (NCT01300923)
Timeframe: Week 10
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
ABC Irritability | ABC Social Withdrawal | ABC Stereotypy | ABC Hyperactivity | ABC Inappropriate Speech | ABC Social Avoidance | |
Acamprosate Treatment Group | 7.0 | 4.1 | 6.0 | 11.0 | 4.8 | 1.6 |
The VABS-II is a semi-structured interview designed to assess adaptive functioning in communication, daily living, socialization and motor skills. Recognizing that language is a major area of impairment in the study population, the Communication Domain (99 Items from 0-198), in particular the Expressive Subdomain (54 Items from 0-108) are of interest in this study. Items arranged in a developmental sequence are rated on a 3-point scale. Each item is scored from 0 (never performs the behavior) to 3 (usually performs the behavior independently). Higher scores indicate higher adaptive functioning. Differences between Baseline and Week 10 are used as an indicator of change. (NCT01300923)
Timeframe: Week 10
Intervention | units on a scale (Mean) | |
---|---|---|
Communication Domain | Expressive Communication | |
Acamprosate Treatment Group | 66.6 | 78.9 |
1 review available for taurine and Fragile X Syndrome
Article | Year |
---|---|
Treatment of the psychiatric problems associated with fragile X syndrome.
Topics: Acamprosate; Adult; Animals; Child; Female; Fragile X Syndrome; Humans; Lovastatin; Male; Mice; Mino | 2015 |
1 trial available for taurine and Fragile X Syndrome
Article | Year |
---|---|
Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.
Topics: Acamprosate; Adolescent; Biomarkers; Brain-Derived Neurotrophic Factor; Child; Dose-Response Relatio | 2013 |
9 other studies available for taurine and Fragile X Syndrome
Article | Year |
---|---|
Role of Taurine in Testicular Function in the Fragile x Mouse.
Topics: Animals; Cyclin-Dependent Kinase 5; Dietary Supplements; Disease Models, Animal; Fragile X Mental Re | 2019 |
Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome.
Topics: Acamprosate; Animals; Animals, Genetically Modified; Behavior, Animal; Calbindins; Disease Models, A | 2018 |
Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker.
Topics: Acamprosate; Adolescent; Amyloid beta-Protein Precursor; Case-Control Studies; Child; Child Developm | 2014 |
Taurine recovers mice emotional learning and memory disruptions associated with fragile x syndrome in context fear and auditory cued-conditioning.
Topics: Acoustic Stimulation; Animals; Conditioning, Psychological; Cues; Emotional Intelligence; Emotions; | 2015 |
Taurine improves congestive functions in a mouse model of fragile X syndrome.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Fragile X Syndrome; Mice; Taurine | 2009 |
Brief report: acamprosate in fragile X syndrome.
Topics: Acamprosate; Adolescent; Autistic Disorder; Communication; Comorbidity; Fragile X Syndrome; Humans; | 2010 |
Taurine regulation of short term synaptic plasticity in fragile X mice.
Topics: Animals; Binding Sites; Disease Models, Animal; Electric Stimulation; Excitatory Postsynaptic Potent | 2010 |
Neuro-endocrine basis for altered plasma glucose homeostasis in the Fragile X mouse.
Topics: Animals; Blood Glucose; Calcium Channels; Dietary Supplements; Disease Models, Animal; Fragile X Men | 2010 |
Alterations of amino acids and monoamine metabolism in male Fmr1 knockout mice: a putative animal model of the human fragile X mental retardation syndrome.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Alanine; Amino Acids; Animals; Aspartic Acid; Brain; Brain St | 2001 |